Want to see CUPR full AI Analyst Report?
CUPR Stock Chart & Stats
$2.79
--
Market closed
$2.79
--
Day’s Range― - ―
52-Week Range$1.45 - $14.80
Previous CloseN/A
VolumeN/A
Average Volume (3M)152.41K
Market Cap
$11.19M
Enterprise Value$15.53T
Total Cash (Recent Filing)$3.12M
Total Debt (Recent Filing)$482.72K
Price to Earnings (P/E)―
Beta1.06
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding5,891,506
10 Day Avg. Volume175,550
30 Day Avg. Volume152,407
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)2.08
Price to Sales (P/S)211.01
P/FCF Ratio-1.15
Enterprise Value/Market Cap1.39M
Enterprise Value/Revenue579.61M
Enterprise Value/Gross Profit-941.13M
Enterprise Value/Ebitda-5.52M
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Profitable Clinic AcquisitionThe proposed acquisition would add a profitable, seven-clinic operating platform with established revenue and positive EBITDA. It could diversify Cuprina beyond its existing products, expand its clinical footprint, and create operating synergies with wound-care and collagen technologies.
New Growth FundingThe completed equity raise provides capital for R&D, equipment, infrastructure, market expansion, brand building, and working capital. Those investments could strengthen the biomedical platform and support broader commercialization across several healthcare-related businesses.
Modest Absolute DebtRelatively modest debt limits immediate interest and refinancing pressure compared with a highly leveraged balance sheet. This gives management more flexibility to direct newly raised funds toward operations, product development, and acquisitions while preserving some financial capacity.
Bears Say
Deepening UnprofitabilityThe shift to negative gross profit alongside sharply wider operating and net losses indicates that the current business model is not yet generating sustainable operating leverage. Continued losses may require additional funding and make successful execution of expansion plans more important.
Severe Cash BurnPersistent negative operating and free cash flow show that the company is not self-funding its operations. The sharp deterioration in 2025 increases dependence on external capital, limits resilience during execution setbacks, and could constrain investment if financing becomes less available.
Historical Balance-sheet StrainSeveral years of negative equity indicate substantial historical balance-sheet strain despite the 2025 improvement. The company remains dependent on maintaining adequate capitalization, and future expansion or losses could again pressure equity and reduce financial stability.
Cuprina Holdings (Cayman) Limited Class A News
CUPR FAQ
What was Cuprina Holdings (Cayman) Limited Class A’s price range in the past 12 months?
Cuprina Holdings (Cayman) Limited Class A lowest stock price was $1.45 and its highest was $14.80 in the past 12 months.
What is Cuprina Holdings (Cayman) Limited Class A’s market cap?
Cuprina Holdings (Cayman) Limited Class A’s market cap is $11.19M.
When is Cuprina Holdings (Cayman) Limited Class A’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Cuprina Holdings (Cayman) Limited Class A’s earnings last quarter?
Currently, no data Available
Is Cuprina Holdings (Cayman) Limited Class A overvalued?
According to Wall Street analysts Cuprina Holdings (Cayman) Limited Class A’s price is currently Overvalued.
Does Cuprina Holdings (Cayman) Limited Class A pay dividends?
Cuprina Holdings (Cayman) Limited Class A does not currently pay dividends.
What is Cuprina Holdings (Cayman) Limited Class A’s EPS estimate?
Cuprina Holdings (Cayman) Limited Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cuprina Holdings (Cayman) Limited Class A have?
Cuprina Holdings (Cayman) Limited Class A has 5,891,506 shares outstanding.
What happened to Cuprina Holdings (Cayman) Limited Class A’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cuprina Holdings (Cayman) Limited Class A?
Currently, no hedge funds are holding shares in CUPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cuprina Holdings (Cayman) Limited Class A
Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its flagship MEDIFLY brand, which features medical-grade sterile blowfly larvae bio-dressing products designed to function as an effective biological debridement tool for chronic wounds. Beyond its core wound care business, Cuprina also extends its operations into the broader health and beauty market, where it provides a range of cosmeceutical items.
Technical Analysis
GeoVax Labs
―
HCW Biologics
―
Calidi Biotherapeutics
―
Psyence Biomedical
―
Aspire Biopharma Holdings
―
Ownership Overview
―
Insiders
0.03% Mutual Funds
― Other Institutional Investors
99.97% Public Companies and
Individual Investors